Abstracts of the XXXVII Annual Congress of the European Society for Artificial Organs, 8-11 September 2010, Skopje, Macedonia.

摘要

Citrate has many characteristics of the ideal anticoagulant for hemodialysis. Its anticoagulant effect is excellent and is limited to the dialysis circuit. In addition to inhibiting coagulation, it reduces platelet deposition on the dialyser membrane. By chelating calcium and magnesium, citrate reduces some of the effects of blood interaction with the dialyzer membrane, which are calcium and magnesium dependent, thus improving biocompatibility of dialysis circuit. Using citrate, we avoid heparin-induced thrombocytopenia. Citrate is easily dialyzable (molecular weight of trisodium citrate is 294 Da), its removal during high-flux dialysis is 83%. The cost of citrate is low. The major issue preventing wider use of citrate is the complexity of citrate anticoagulation protocols.